1. Genome editing in mammalian cells using the CRISPR type I-D nuclease.
- Author
-
Osakabe K, Wada N, Murakami E, Miyashita N, and Osakabe Y
- Subjects
- CRISPR-Associated Proteins chemistry, CRISPR-Associated Proteins genetics, Endodeoxyribonucleases chemistry, Endodeoxyribonucleases genetics, HEK293 Cells, Humans, Mutagenesis, Mutation, CRISPR-Associated Proteins metabolism, CRISPR-Cas Systems, Endodeoxyribonucleases metabolism, Gene Editing
- Abstract
Adoption of CRISPR-Cas systems, such as CRISPR-Cas9 and CRISPR-Cas12a, has revolutionized genome engineering in recent years; however, application of genome editing with CRISPR type I-the most abundant CRISPR system in bacteria-remains less developed. Type I systems, such as type I-E, and I-F, comprise the CRISPR-associated complex for antiviral defense ('Cascade': Cas5, Cas6, Cas7, Cas8 and the small subunit) and Cas3, which degrades the target DNA; in contrast, for the sub-type CRISPR-Cas type I-D, which lacks a typical Cas3 nuclease in its CRISPR locus, the mechanism of target DNA degradation remains unknown. Here, we found that Cas10d is a functional nuclease in the type I-D system, performing the role played by Cas3 in other CRISPR-Cas type I systems. The type I-D system can be used for targeted mutagenesis of genomic DNA in human cells, directing both bi-directional long-range deletions and short insertions/deletions. Our findings suggest the CRISPR-Cas type I-D system as a unique effector pathway in CRISPR that can be repurposed for genome engineering in eukaryotic cells., (© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2021
- Full Text
- View/download PDF